| Recruiting | An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in S NCT06855706 | Roswell Park Cancer Institute | N/A |
| Withdrawn | Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer NCT05672095 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Recruiting | MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer NCT06483048 | Mayo Clinic | Phase 1 |
| Recruiting | Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patien NCT05231122 | Roswell Park Cancer Institute | Phase 2 |
| Recruiting | Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study NCT06295965 | University of Washington | — |
| Recruiting | Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity NCT05920798 | Mayo Clinic | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers NCT05691504 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment NCT04919629 | Roswell Park Cancer Institute | Phase 2 |
| Recruiting | Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS NCT05554328 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumo NCT05564377 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopia NCT04781088 | Floor Backes, MD | Phase 2 |
| Withdrawn | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer NCT04498520 | Pamela Munster | Phase 1 |
| Active Not Recruiting | Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Ca NCT04387227 | University of Washington | Phase 2 |
| Completed | Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, NCT04753216 | Northwestern University | Phase 2 |
| Recruiting | Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer NCT04469764 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Terminated | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal NCT03924245 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Active Not Recruiting | A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With NCT04092270 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer NCT04055649 | Ira Winer | Phase 2 |
| Active Not Recruiting | Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurr NCT04034927 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, o NCT04019288 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatr NCT04213794 | Mayo Clinic | EARLY_Phase 1 |
| Recruiting | Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers NCT03968406 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients NCT03539406 | Radboud University Medical Center | Phase 1 |
| Active Not Recruiting | Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistan NCT03907527 | Precigen, Inc | Phase 1 |
| Active Not Recruiting | Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fall NCT03586661 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovaria NCT03776812 | Corcept Therapeutics | Phase 2 |
| Terminated | Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen i NCT03691376 | Roswell Park Cancer Institute | Phase 1 |
| Active Not Recruiting | Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer NCT03732950 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Withdrawn | PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Per NCT02948101 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF NCT03604315 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab NCT03412630 | ECOG-ACRIN Cancer Research Group | N/A |
| Active Not Recruiting | Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallo NCT03579316 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With NCT03508570 | M.D. Anderson Cancer Center | Phase 1 |
| Withdrawn | Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or NCT02756130 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Completed | Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian NCT03552471 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Withdrawn | Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Perito NCT02833506 | Roswell Park Cancer Institute | Phase 1 |
| Active Not Recruiting | Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary NCT03017131 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, NCT03206047 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer NCT03325634 | University of Colorado, Denver | Phase 1 |
| Completed | Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tu NCT02953457 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ova NCT03685695 | Roswell Park Cancer Institute | Phase 2 |
| Active Not Recruiting | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With R NCT02839707 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Completed | Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, NCT03026062 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ova NCT02627443 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, F NCT02923739 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent O NCT02996825 | City of Hope Medical Center | Phase 1 |
| Completed | Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Pri NCT03029598 | University of Washington | Phase 1 / Phase 2 |
| Completed | Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian NCT02901899 | Northwestern University | Phase 2 |
| Completed | Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, NCT02853318 | Roswell Park Cancer Institute | Phase 2 |
| Active Not Recruiting | Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, NCT02595892 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Perit NCT02657928 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Re NCT02502266 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Active Not Recruiting | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared NCT02446600 | National Cancer Institute (NCI) | Phase 3 |
| Withdrawn | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent NCT02627430 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persisten NCT02569957 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Pri NCT02498600 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT02312245 | Mayo Clinic | Phase 2 |
| Withdrawn | Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian NCT02470559 | Barbara Ann Karmanos Cancer Institute | Phase 1 |
| Completed | Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary P NCT02315430 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cance NCT02364713 | Mayo Clinic | Phase 2 |
| Completed | p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer NCT02275039 | City of Hope Medical Center | Phase 1 |
| Completed | Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube NCT02283658 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian NCT02208375 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, NCT02101775 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid T NCT02142803 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopi NCT01970722 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Can NCT02068794 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavi NCT02111941 | Mayo Clinic | EARLY_Phase 1 |
| Terminated | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal NCT02059265 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tub NCT01716715 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cav NCT01720173 | Gynecologic Oncology Group | Phase 2 |
| Completed | Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Pri NCT01606241 | Mayo Clinic | Phase 1 |
| Completed | EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent O NCT01489371 | Gynecologic Oncology Group | Phase 1 |
| Completed | Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Per NCT01540565 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithe NCT01492920 | Gynecologic Oncology Group | Phase 3 |
| Completed | Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian E NCT01468909 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients Wi NCT01459380 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, NCT01372787 | Gynecologic Oncology Group | — |
| Completed | A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian T NCT01283035 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovari NCT01305213 | National Cancer Institute (NCI) | Phase 2 |
| Completed | TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients Wit NCT01294293 | Gynecologic Oncology Group | Phase 1 |
| Completed | Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinom NCT01264432 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Ca NCT00886691 | GOG Foundation | Phase 2 |
| Completed | Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, NCT00888615 | GOG Foundation | Phase 2 |
| Completed | Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, NCT01199263 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer NCT01039207 | Gynecologic Oncology Group | Phase 2 |
| Completed | RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Canc NCT01175343 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer NCT01145430 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelia NCT01074411 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian C NCT01012817 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Isl NCT01010126 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Ut NCT00954174 | GOG Foundation | Phase 3 |
| Completed | Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy NCT00892736 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube NCT01001910 | Albert Einstein College of Medicine | Phase 2 |
| Completed | A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithel NCT00671788 | Gynecologic Oncology Group | Phase 2 |
| Completed | Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tub NCT00602277 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Pa NCT00565851 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Prima NCT00096200 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Collecting Tumor Samples From Patients With Gynecological Tumors NCT00897442 | Gynecologic Oncology Group | — |